Medpace Holdings, Inc. $MEDP Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH cut its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 13.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 21,416 shares of the company’s stock after selling 3,271 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.08% of Medpace worth $11,011,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Wasatch Advisors LP grew its holdings in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after acquiring an additional 116,354 shares during the period. Mawer Investment Management Ltd. boosted its position in shares of Medpace by 17.4% during the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after purchasing an additional 121,213 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Medpace by 15.1% in the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock worth $193,269,000 after purchasing an additional 81,637 shares during the last quarter. TD Asset Management Inc grew its stake in shares of Medpace by 15.6% in the 2nd quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock worth $143,636,000 after purchasing an additional 61,764 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its holdings in shares of Medpace by 11.4% in the 2nd quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock worth $139,740,000 after purchasing an additional 45,435 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the topic of several recent research reports. Barclays lifted their price target on shares of Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a research report on Monday, December 15th. Truist Financial set a $555.00 target price on Medpace in a research report on Monday, October 27th. BMO Capital Markets started coverage on Medpace in a report on Thursday, November 13th. They set a “market perform” rating and a $600.00 target price for the company. Mizuho set a $660.00 price target on Medpace in a research report on Friday, January 9th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Medpace has a consensus rating of “Reduce” and an average price target of $491.27.

Insider Transactions at Medpace

In related news, CFO Kevin M. Brady sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the completion of the sale, the chief financial officer directly owned 6,000 shares in the company, valued at approximately $3,542,100. This trade represents a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the transaction, the vice president directly owned 27,500 shares in the company, valued at $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 387,925 shares of company stock valued at $233,386,647 over the last three months. 20.30% of the stock is owned by corporate insiders.

Medpace Stock Down 3.0%

MEDP opened at $588.05 on Friday. The firm has a market capitalization of $16.57 billion, a P/E ratio of 41.12, a PEG ratio of 1.97 and a beta of 1.43. The stock has a fifty day moving average of $583.65 and a 200-day moving average of $521.26. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same period in the previous year, the firm earned $3.01 earnings per share. Medpace’s quarterly revenue was up 23.7% on a year-over-year basis. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.